PYXS Insider Trading

Insider Ownership Percentage: 2.20%
Insider Buying (Last 12 Months): $293,918.00
Insider Selling (Last 12 Months): $5,324,571.05

Pyxis Oncology Insider Trading History Chart

This chart shows the insider buying and selling history at Pyxis Oncology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pyxis Oncology Share Price & Price History

Current Price: $1.95
Price Change: Price Decrease of -0.02 (-1.02%)
As of 10/5/2022 01:00 AM ET

This chart shows the closing price history over time for PYXS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Pyxis Oncology Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/21/2022Mark ChinDirectorSell1,745,761$3.05$5,324,571.05View SEC Filing Icon  
12/8/2021Darren S. ClineDirectorBuy10,000$9.39$93,900.00View SEC Filing Icon  
11/18/2021Thomas CivikDirectorBuy15,700$12.74$200,018.00View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Pyxis Oncology (NASDAQ:PYXS)

71.59% of Pyxis Oncology stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at PYXS by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Pyxis Oncology Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/18/2022Goldman Sachs Group Inc.12,882$31K0.0%N/A0.039%Search for SEC Filing on Google Icon
8/15/2022State Street Corp30,989$74K0.0%-78.6%0.094%Search for SEC Filing on Google Icon
8/15/2022Acuta Capital Partners LLC645,149$1.54M0.9%+222.6%1.966%Search for SEC Filing on Google Icon
8/15/2022Laurion Capital Management LP3,170,803$7.55M0.1%+159.9%9.662%Search for SEC Filing on Google Icon
8/15/2022Millennium Management LLC142,815$0.34M0.0%N/A0.435%Search for SEC Filing on Google Icon
8/13/2022Renaissance Technologies LLC75,371$0.18M0.0%N/A0.230%Search for SEC Filing on Google Icon
8/12/2022Northern Trust Corp17,742$42K0.0%-79.9%0.054%Search for SEC Filing on Google Icon
8/12/2022Credit Suisse AG965,465$2.30M0.0%N/A2.942%Search for SEC Filing on Google Icon
6/7/2022Bank of America Corp DE20,278$82K0.0%-29.1%0.062%Search for SEC Filing on Google Icon
5/16/2022State Street Corp144,795$0.59M0.0%+55.9%0.441%Search for SEC Filing on Google Icon
5/16/2022Ghost Tree Capital LLC75,000$0.30M0.1%-74.6%0.228%Search for SEC Filing on Google Icon
5/13/2022Tekla Capital Management LLC708,303$2.63M0.1%+424.7%2.157%Search for SEC Filing on Google Icon
5/13/2022Vanguard Group Inc.526,309$2.13M0.0%+1.2%1.603%Search for SEC Filing on Google Icon
5/12/2022BlackRock Inc.520,901$2.10M0.0%+1.4%1.586%Search for SEC Filing on Google Icon
5/12/2022Citigroup Inc.233,129$0.94M0.0%+7,171.6%0.710%Search for SEC Filing on Google Icon
5/11/2022Bank of New York Mellon Corp32,589$0.13M0.0%+69.0%0.099%Search for SEC Filing on Google Icon
2/16/2022Ghost Tree Capital LLC295,000$3.24M1.2%N/A0.900%Search for SEC Filing on Google Icon
2/15/2022Laurion Capital Management LP1,162,332$12.75M0.1%N/A3.548%Search for SEC Filing on Google Icon
2/15/2022Davidson Kempner Capital Management LP10,000$0.11M0.0%N/A0.031%Search for SEC Filing on Google Icon
2/14/2022Citadel Advisors LLC1,521,617$16.48M0.0%N/A4.644%Search for SEC Filing on Google Icon
2/14/2022Deerfield Management Company L.P. Series C311,754$3.42M0.1%N/A0.952%Search for SEC Filing on Google Icon
2/14/2022Hhlr Advisors LTD.764,406$8.39M0.1%N/A2.333%Search for SEC Filing on Google Icon
2/14/2022Perceptive Advisors LLC1,944,114$21.33M0.3%N/A5.934%Search for SEC Filing on Google Icon
2/14/2022Sandia Investment Management LP10,000$0.11M0.0%N/A0.031%Search for SEC Filing on Google Icon
2/14/2022Ghisallo Capital Management LLC30,000$0.33M0.0%N/A0.092%Search for SEC Filing on Google Icon
2/8/2022Northern Trust Corp89,235$0.98M0.0%N/A0.272%Search for SEC Filing on Google Icon
2/2/2022New York State Common Retirement Fund6,277$69K0.0%N/A0.019%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Pyxis Oncology logo
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Read More on Pyxis Oncology

Today's Range

Now: $1.95
Low: $1.92
High: $2.00

50 Day Range

MA: $2.55
Low: $1.88
High: $3.03

52 Week Range

Now: $1.95
Low: $1.71
High: $19.00

Volume

16,393 shs

Average Volume

127,612 shs

Market Capitalization

$64.03 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Pyxis Oncology?

Pyxis Oncology's top insider investors include:
  1. Darren S Cline (Director)
  2. Mark Chin (Director)
  3. Thomas Civik (Director)
Learn More about top insider investors at Pyxis Oncology.